论文部分内容阅读
目的探讨阿克拉霉素、阿糖胞苷联合粒细胞集落刺激因子(G-CSF)治疗复发急性髓系白血病的临床效果。方法 2008年1月至2010年10月收治复发急性髓系白血病患者47例,分为治疗组24例,对照组23例,观察两组临床疗效及不良反应。结果治疗组总有效率为87.5%,对照组总有效率为73.9%;治疗组不良反应发生率为16.7%,对照组不良反应发生率为47.8%。结论阿克拉霉素、阿糖胞苷联合G-CSF治疗复发急性髓系白血病,是具有高效低毒的新型化疗方案,以小剂量、低浓度、持续作用、合理配伍为特色,疗效肯定,不良应较轻,无严重毒副作用。
Objective To investigate the clinical effects of aclacinomycin, cytarabine and granulocyte-colony stimulating factor (G-CSF) in the treatment of recurrent acute myeloid leukemia. Methods From January 2008 to October 2010, 47 patients with recurrent acute myeloid leukemia were divided into treatment group (24 cases) and control group (23 cases). Clinical efficacy and adverse reactions were observed in both groups. Results The total effective rate was 87.5% in the treatment group and 73.9% in the control group. The incidence of adverse reactions in the treatment group was 16.7% and that in the control group was 47.8%. Conclusion Acremycin and cytarabine combined with G-CSF in the treatment of recurrent acute myeloid leukemia is a new chemotherapy regimen with high efficiency and low toxicity. It has the characteristics of low dose, low concentration, sustained action and reasonable compatibility, with positive curative effect and poor efficacy Should be lighter, no serious side effects.